KALIUM DI MULTIDRUG RESISTANCE TUBERKULOSIS DENGAN PENGOBATAN KANAMISIN
Main Authors: | Suparyatmo, J.B., AS, B. Rina, Harsini, Harsini, Sukma, Sukma |
---|---|
Format: | Article info application/pdf eJournal |
Bahasa: | eng |
Terbitan: |
PERHIMPUNAN DOKTER SPESIALIS PATOLOGI KLINIK INDONESIA
, 2016
|
Subjects: | |
Online Access: |
http://www.indonesianjournalofclinicalpathology.or.id/index.php/patologi/article/view/488 http://www.indonesianjournalofclinicalpathology.or.id/index.php/patologi/article/view/488/233 |
Daftar Isi:
- Multidrug-Resistant Tuberculosis (MDR-TB) with bacillary resistance to at least isoniazid and rifampicin in vitro is a worldwide phenomenon. For MDR-TB second-line antibiotic agents that are more potent and more toxic must be used. . One of them is kanamycin given intravenously every day for six (6) months therapy. Kanamycin is nephrotoxic and can lead to hypokalemia. This study is carried out to know the comparison between the potasium level before and after kanamycin therapy (2, 4 and 6 months after therapy). This study is a cohort retrospective design, comprising 34 patients who had a potassium baseline before therapy in Moewardi Hospital, Surakarta from January 2011–August 2012. The characteristic data included: age, sex, weight and comorbidity. The potassium level after 2, 4 and 6 months post therapy was compared with the potassium data baseline using One Way ANOVA test with p< 0.05, CI 95%. The difference between the potassium level after 6 months therapy and potassium baseline was significant, p < 0.05. However, the difference of the kalium level after 2 and 4 months after therapy was not significant, p > 0.05. Hypokalemia occurred in 6 patients after 2 months therapy, 8 patients after 4 months therapy and 3 patients after 6 months therapy. There was a significant difference between the potassium level after 6 months therapy and potassium baseline. Further study should be continued to know the existence of hypokalemia among MDR-TB patients